57 results about "Fibrinogen" patented technology

Disclosed is a method for filtering a fibrinogen composition, including the following steps: a) purifying the fibrinogen composition by chromatographic purification using an elution buffer comprising arginine; b) optionally, at least one step of filtering the fibrinogen composition obtained by chromatographic elution in step a), on a filter having a pore size of between 0.08 μm and 0.22 μm, c) filtering the fibrinogen composition obtained by chromatographic elution in step a), or optionally obtained in step b), on a symmetrical filter having a pore size of between 15 nm and 25 nm, and preferably between 18 nm and 22 nm, and d) recovering the resulting fibrinogen solution, the filtering method being carried out without adding arginine after step a), at a high capacity and without a prior freezing and / or thawing step.

A system for determining a functional fibrinogen concentration from a patient's coagulating blood or blood plasma sample is configured to obtain a signal representing physical or biochemical properties of the developing fibrin network during coagulation of the patient's blood or blood plasma sample over time, determine the fibrinogen concentration based on one or more values of one or more features of the signal with the help of a learned function which maps values of the feature(s) to functional fibrinogen concentrations, and output the fibrinogen concentration, e.g. on a display. The feature(s) include(s) multiple of features related to 1) a maximum value of the gradient of the signal, 2) the maximum of the second derivative of the signal, 3) a difference between the maximum and the minimum of the signal, and 4) the minimum of the second derivative of the signal, or at least feature 1) or 2).

The invention discloses a preparation method of a fibrous protein / bacterial cellulose efficient hemostatic patch. The preparation method comprises the following steps: (1) in-situ preparation of large-aperture bacterial cellulose; (2) infiltration of fibrinogen in the large-aperture bacterial cellulose; and (3) enzyme digestion and freeze-drying treatment of fibrinogen. The problems that fibrinogen is fast in degradation and poor in stability and mechanical property are solved, the prepared fibrous protein / bacterial cellulose efficient hemostatic patch can prevent secondary bleeding and avoid thrombus to a certain extent, the preparation process is simple and easy to implement, and large-scale preparation and storage can be achieved.

The utility model discloses a hemostasis assist device for vascular surgery, which relates to the technical field of medical instruments, and comprises a fixing mechanism, a vascular surgery hemostasis mechanism is arranged in the fixing mechanism, the vascular surgery hemostasis mechanism comprises a knob, and the bottom of the knob is fixedly connected with a threaded column. According to the hemostasis mechanism for the vascular surgery department, during hemostasis, the periphery of a wound can be heated through the heating block across the replacement pad, the temperature of the periphery of the wound reaches 37-42 DEG C, activation of platelets can be accelerated to a certain extent at the temperature, energy metabolism of the platelets is accelerated within the temperature range, and the blood circulation is accelerated. The increase of the concentration of calcium ions in the blood platelets is an important signal of platelet activation, and the increased concentration of the calcium ions can promote the activation of glycoprotein receptors on platelet membranes, so that the binding capacity of the blood platelets and fibrinogen is enhanced, the aggregation of the blood platelets is accelerated, and the hemostasis speed is accelerated.

The invention relates to the technical field of electrochemical sensing, in particular to a multi-channel electrochemical aptamer sensor and a preparation method and application thereof.The multi-channel electrochemical aptamer sensor adopts a commercial silk-screen printing electrode and is combined with a polymer substrate material for amplifying electrochemical signals, and the electrochemical aptamer sensor is prepared. According to the present invention, the corresponding aptamer is fixed by using the gold nanoparticle through the chemical bond so as to specifically detect the three hemorrhage conversion biomarkers after acute cerebral infarction, such as human matrix metalloproteinase (MMP-9), fibrinogen (FN) and plasminogen activation inhibitor (PAI-1); wherein the FN and the PAI-1 are detected through an electrochemical aptamer sensor method for the first time, and simultaneous detection of the three biomarkers is realized through integration with commercial multi-channel micro electrochemical equipment.

The present application relates to a method for preparing and expanding a TSCM cell in vitro. Specifically, the method comprises: 1) obtaining an isolated CD8+ T cell; 2) activating the CD8+ T cell; 3) mixing the activated CD8+ T cell, a fibrinogen solution and a thrombin solution, and culturing same under conditions suitable for cell growth, so as to obtain a TSCM cell culture; and 4) bringing the culture into contact with a dispase so as to obtain a TSCM cell. The present application also relates to a kit for preparing and expanding a TSCM cell in vitro, the use of fibrinogen and thrombin in the preparation of a kit for preparing and expanding a TSCM cell in vitro, and a TSCM cell obtained by means of the method or kit of the present application.

The invention belongs to the technical field of biomedical material engineering, and discloses a hydrogel scaffold used for 3D tumor sphere culture and drug screening, the scaffold is formed by four-arm polyethylene glycol maleimide, fibrinogen and thrombin through Michael addition crosslinking and biopolymerization synergistically, the elastic modulus of 10-1000 Pa can be adjusted by regulating and controlling the proportion of all the components, and the hydrogel scaffold can be used for 3D tumor sphere culture and drug screening. Gel forming is completed within 5 min at the room temperature. The scaffold has the biological activity of fibrous protein and the structural stability of polyethylene glycol, can efficiently support HCT116 cells to form high-activity tumor balls, accurately simulate the in-vivo tumor microenvironment and remarkably improve the accuracy and repeatability of drug screening, is easy and convenient to operate, is compatible with a standard pore plate high-throughput platform and is suitable for drug sensitivity detection of personalized treatment of tumors.

The invention discloses a special constant-temperature thawing and dissolving device for medical fibrinogen, and relates to the technical field of medical auxiliary instruments, the special constant-temperature thawing and dissolving device for medical fibrinogen comprises a heat preservation box body, and a circulating hot water supply device, a constant-temperature preheating tank, an infusion doser and a dissolving tank which are integrated in the heat preservation box body, the circulating hot water supply device is arranged on one side of an inner cavity of the heat preservation box body; a porous placing frame is placed in the constant-temperature preheating tank, a disposable pipetting mechanism is arranged on the infusion doser, a magnetic shaking table is installed in the center of an inner cavity of the dissolving tank, the preheating function and the dissolving function are integrated into one device, hot water is conveyed to the constant-temperature preheating tank through the circulating hot water supply device for preliminary preheating, and then medicine bottles are transferred to the dissolving tank for dissolving; the process is orderly linked, the tedious step-by-step operation is avoided, the pollution risk is reduced, the operation is simplified, medical fibrinogen thawing and dissolving can be more efficiently and stably completed, and the working efficiency and quality are improved.

The invention relates to a freeze drying method of instant fibrinogen, and belongs to the technical field of blood product preparation. The method comprises the steps of plasma pre-fusion, centrifugal separation, FI extraction, FI precipitation, dissolution and filtration, polyethylene glycol purification and separation, S / D inactivation, ethanol purification and separation, glycine purification and separation, ultrafiltration dialysis, preparation, degerming and subpackaging, freeze-drying and capping and the like. Wherein the freeze-drying process comprises four stages of pre-freezing, primary sublimation, desorption drying and plug pressing, and finally dry heat inactivation treatment is carried out. According to the method, efficient extraction and purification of fibrinogen are achieved by accurately controlling the temperature, the time, the pH value and the component proportion of various solutions in each step, and the obtained product has good instant dissolving performance and can be used in the medical fields of clinical hemostasis, tissue repair and the like.

The application belongs to the technical field of biological medicine, and discloses application of a simulation polypeptide containing a fibrinogen RGD module in preparation of a medicine for preventing and / or treating Parkinson's disease. The sequence of the simulation polypeptide containing the fibrinogen RGD module is Gly-Arg-Gly-Asp-Ser-Pro-Lys-Asn-Pro-Ser-Cys. The applicant of the application finds that FG abnormally accumulates in the substantia nigra compacta of a PD mouse, and the FG excessively accumulated in the brain may promote abnormal aggregation of alpha-syn of dopaminergic neurons through mediation of an alpha v beta 3 integrin receptor. The simulation polypeptide provided by the application can effectively inhibit abnormal aggregation of alpha-syn of dopaminergic neurons caused by the abnormally accumulated FG in the brain and death of the dopaminergic neurons, improve the motor ability of the PD mouse modeled by MPTP, and provide a new target and thought for PD treatment.

A protein nanospheres and method to treat dysfunction from chemotherapy and immunosuppressive therapy, and a manufacture of fibrinogen-coated albumin spheres (FAS) and High-Fibrinogen Spheres (HFS) which have higher concentrations of fibrinogen molecules per sphere than FAS, and their use for medical treatments. Both kinds of nanoparticles are effective in the mitigation of the toxic effects of certain chemotherapeutic and radiological agents that are typically used in the treatment of cancer, or the treatment of autoimmune diseases, or for patients with both diseases. FAS and HFS can exert their beneficial effects via a variety of mechanisms which match the need of the body for specific cell types, including any of the subgroups of T cells and antibody producing cells, the relative concentration of each kind is vital to the balance between tumor surveillance and autoimmune disease suppression.

The present technique pertains to a method of preparation of a succinylated collagen-fibrinogen hydrogel and a succinylated collagen-fibrinogen hydrogel prepared thereby. The method of preparation of a succinylated collagen-fibrinogen hydrogel according to the present technique can produce a collagen-based bio-substance in a simple process, wherein collagen can be prevented from being entangled and an improvement can be brought about in hydrophilicity, cell growth rate, cell compatibility, and cell diffusion capability, whereby the collagen-based bio-substance exhibits excellent biocompatibility in vivo.

Fibrinogen-coated Albumin Nanospheres (FAS) has shown that it can mobilize bone marrow cells into the blood which then go to injured soft and hard tissues to achieve accelerated repair. It is hypothesize that (a) brain injuries caused by low-dose irradiation under simulated microgravity can be mitigated by the administration of FAS; and (b) the mechanism is from acceleration of neo-vascularization, proven by lineage study of GFP-labeled bone marrow cells implanted into compatible non-GFP animals before injury, which regenerate into functional GFP-brain cells after FAS treatment.

The invention relates to an application of Fgl2 gene knockout in antagonism of new coronavirus. In the technical scheme provided by the invention, a new crown infected mouse model is established through two SARS-CoV-2 mouse adaptive strains, namely, an MA17 strain and an MASCp36 strain, and it is verified that virus infection can promote Fgl2 expression up-regulation and fibrinogen deposition in mouse lung tissues; in addition, an SARS-CoV-2 mouse adaptive strain MA17 is utilized to infect an Fgl2 gene knockout mouse to prove that the Fgl2 gene knockout can antagonize lung inflammation infiltration, tissue damage, thromboembolism, fibrinogen deposition and fibrosis formation caused by virus infection, so that the occurrence of severe case and death of the mouse is reduced.

The invention relates to a method for separating and purifying fibrinogen with low impure protein, and belongs to the technical field of blood product production. The method comprises the following steps: preparing a raw material component I, dissolving and filtering an FI precipitate, dissolving with a dissolving solution A, and filtering to obtain a filtrate A; purifying and separating polyethylene glycol, adjusting the pH value of the filtrate A, adding polyethylene glycol to precipitate, dissolving the precipitate by using the dissolving solution B, and filtering; s / D inactivation: adding an S / D solution into the filtrate B for virus inactivation; ethanol purification and separation: adding ethanol to the inactivated solution to precipitate protein, dissolving the precipitate with a dissolving solution B, and filtering; purifying and separating glycine, adding glycine precipitation protein into the filtrate C, dissolving the precipitate by using the dissolving solution C, and filtering; carrying out ultrafiltration dialysis, and dialyzing and concentrating the filtrate D; preparation: diluting the stock solution to a proper concentration; the semi-finished product is subpackaged, freeze-dried and subjected to dry heat inactivation treatment. The method can effectively remove impure proteins, improve the purity of fibrinogen and ensure the product safety.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to application of herba artemisiae scopariae and an ethanol herba artemisiae scopariae extract in a medicine for treating autoimmune hepatitis, the ethanol herba artemisiae scopariae extract can reduce ALT and AST of a patient suffering from the autoimmune hepatitis, can effectively reverse liver tissue lesions of the patient suffering from the autoimmune hepatitis, and has the advantages that the curative effect is good, and the curative effect is good. The content of collagen fibrinogen in animal livers is reduced, so that hepatic fibrosis of patients with the autoimmune hepatitis is effectively reversed, proinflammatory factors TNF-alpha, IL-6 and IL-1beta in serum are reduced, the content of an anti-inflammatory factor IL-10 is increased, and the composition has a protective effect on inflammatory injury of liver tissues with the autoimmune hepatitis and can be used for treating the liver with the autoimmune hepatitis. And the content of serum immune globulins IgG and IgM can also be reduced. Through the effects, the oriental wormwood and the ethanol oriental wormwood extract can effectively improve autoimmune hepatitis.

Ischemic heart disease is a leading cause of death and reduced quality of life worldwide. Although revascularization strategies significantly reduce mortality after acute myocardial infarction (MI), many patients with MI develop chronic heart failure over time. We previously reported that human recombinant ANGPTL4 counteracts ischemia-induced vascular endothelial growth factor signaling and disruption of endothelial cell-cell adhesion, thereby inhibiting vascular permeability. We were able to demonstrate that ANGPTL4 administration before MI resulted in protection of the coronary capillary network, no-reflow syndrome, and reduced infarct size in mice. We also demonstrated that the therapeutic effects observed with ANGPTL4 under ischemic conditions were caused by the FLD fragment, not the CCD fragment (WO 2016 / 110498). To further examine the therapeutic potential of the FLD fragment of ANGPTL4 at the onset of reperfusion, we herein used a porcine model, a clinically relevant model of acute myocardial infarction that can be easily and safely translated into patient treatment. We demonstrated that local (antegrade) delivery of the FLD ANGPTL4 to infarcted porcine hearts can efficiently target the lesion site in a clinically relevant manner. A single administration of the FLD of ANGPTL4 improved cardiac function, infarct size, fibrosis, and adverse remodeling parameters 28 days after MI. Short-term MI experiments, coupled with complementary mouse studies, demonstrated myocardial protection. Thus, a single administration of the FLD of ANGPTL4 can reduce ischemia-reperfusion injury and protect against adverse postischemic cardiac remodeling and subsequent ischemic heart failure.

This invention belongs to the field of surgical wound repair technology, and provides a multifunctional composite hydrogel, its preparation method, and its applications. The invention involves mixing fibrinogen, mussel byssal protein, calcium chloride, methacrylated dextran (Dextran-MA), thrombin, dithiothreitol, and a dispersing solvent. The resulting mixture is then gelled to obtain a multifunctional composite hydrogel. Thrombin specifically promotes the cross-linking of fibrinogen to form a biomolecular network; dithiothreitol efficiently mediates the formation of an organic macromolecular network through a Michael addition reaction of Dextran-MA; the introduction of Mfp5, utilizing its abundant catechol groups to form multiple coordination and covalent cross-links with organic / biomolecular macromolecules, significantly enhances the interfacial adhesion strength of the multifunctional composite hydrogel; simultaneously maintaining the biocompatibility, biodegradability, hemostatic properties, anti-inflammatory effects, and healing-promoting capabilities of the multifunctional composite hydrogel.

It provides bodily fluids that serve as raw materials for fibers. [Solution] It is possible to produce fibers, lotions, medicinal solutions, perfumes, etc. from the bodily fluids of humans and animals (cows, horses, pigs, sheep, etc.). The fibers, lotions, medicinal solutions, and perfumes can be produced from the plasma (fibrinogen, etc.) in the bodily fluids.

A method of assessing a COVID-19 infection in a person, the method comprising analysing the concentration or levels of one or more biomarkers in a biological sample from a person, wherein the one or more biomarkers comprises γ' fibrinogen, and wherein concentration or levels of γ' fibrinogen are elevated in a biological sample from a person infected with COVID-19 and can be used for predicting COVID-19 disease severity and / or for making a prognosis of severe COVID-19 disease in a person infected with COVID-19.

The present application belongs to the technical field of blood product preparation, and particularly relates to a method for separating blood coagulation factor VIII and vWF factor from blood plasma. The method comprises the following steps in sequence: after cellulose is balanced, the cellulose is mixed with raw material blood plasma, filtered after stirring, and cellulose precipitate is obtained; after the cellulose precipitate is eluted, the cellulose precipitate is soaked in precipitate dissolving solution, and filtrate is obtained by filtering; the filtrate is subjected to three times of ion exchange chromatography, and factor VIII and / or vWF factor product is obtained. The technical scheme solves the technical problems of the prior art, such as complicated process steps for purifying and enriching human blood coagulation factor VIII and vWF from blood plasma cold precipitate, and unsatisfactory production efficiency and product quality. The cold precipitate protein solution prepared by the method can separate factor VIII, vWF factor and fibrinogen product at the same time through chromatography, improve the utilization rate of plasma protein, and has an ideal application prospect.

The invention belongs to the technical field of cultural relic repair, and particularly relates to a wet adhesion adhesive and a preparation method and application thereof.The adhesive comprises tannic acid, silk fibroin and fibrous protein.The preparation method comprises the steps that a silk fibroin solution is prepared, specifically, a solvent is added into fibroin sponge to be dissolved, the silk fibroin solution is obtained after complete dissolution, and the silk fibroin solution is sealed for use; preparing a tannic acid solution: adding a solvent into tannic acid to dissolve the tannic acid completely to obtain the tannic acid solution, and sealing the tannic acid solution for later use; preparing fibrin: uniformly mixing a fibrinogen solution with CaCl, freezing after solidification, and freeze-drying; fibrin is dissolved in a silk fibroin solution, the fibrin is stirred and dispersed, then tannic acid is added for a reaction, stirring is conducted till the fibrin and the tannic acid are cross-linked to form gel, and the gel is soaked in a tannic acid solution. The silk fibroin tannic acid adhesive is used for cultural relic repair, easy to operate, high in wet adhesion, resistant to aging and suitable for adhesion of cultural relics made of different materials.

This invention provides a method and apparatus for perioperative fibrinogen detection, comprising the following steps: S1, modifying the working electrode surface of a screen-printed electrode with antibody-functionalized self-supporting graphene aerogel material; S2, adding the serum sample to be tested to the modified working electrode surface; S3, adding horseradish peroxidase-labeled fibrinogen detection antibody to the modified working electrode surface; S4, adding a matrix-type TMB solution containing H2O2 to the modified working electrode surface; S5, collecting the reduction current of electrochemically active substances on the electrode surface using a chronoamperometry method; S6, calculating the fibrinogen concentration based on the reduction current value and a standard curve. This invention solves the technical problems of low electron transport efficiency and detection sensitivity, structural instability, poor biocompatibility, and difficulty in enriching electroactive substances when using graphene-modified electrodes.

The present invention provides compositions used for the treatment and / or prevention of protein aggregation disorders. [Solution] Proteopathy encompasses a wide range of ailments, including neurodegenerative diseases (e.g., polyglutamine diseases such as huntingtin in Alzheimer's disease, Parkinson's disease, and Huntington's disease, and prion diseases); amyloidosis of other non-neuronal proteins (especially I1-antitrypsin, immunoglobulin light and heavy chains, lactadherin, apolipoprotein, gelzolin, lysozyme, fibrinogen, atrial natriuretic factor, keratin, lactoferrin, and β-2 microglobulin, etc.); sickle cell disease; cataracts; cystic fibrosis; retinitis pigmentosa; and nephrogenic diabetes insipidus. Administration of sulfatase inhibitors is generally suitable for treating and / or preventing protein toxicity associated with proteopathy. Therefore, the present invention provides compositions comprising sulfatase inhibitors for the treatment of proteopathy.

Methods for diagnosing atopic dermatitis (AD) by using thrombin and / or fibrinogen as biomarkers to determine the presence or severity of AD. Also provided are methods for treating AD by administering to a subject an effective amount of a thrombin inhibitor.

The present invention is directed to a hemostatic textile, comprising: a material comprising a combination of glass fibers and one or more secondary fibers selected from the group consisting of silk fibers; ceramic fibers; raw or regenerated bamboo fibers; cotton fibers; rayon fibers; linen fibers; ramie fibers; jute fibers; sisal fibers; flax fibers; soybean fibers; corn fibers; hemp fibers; lyocel fibers; wool; lactide and / or glycolide polymers; lactide / glycolide copolymers; silicate fibers; polyimide fibers; feldspar fibers; zeolite fibers, zeolite-containing fibers, acetate fibers; and combinations thereof; the hemostatic textile capable of activating hemostatic systems in the body when applied to a wound. Additional cofactors such as thrombin and hemostatic agents such as RL platelets, RL blood cells; fibrin, fibrinogen, and combinations thereof may also be incorporated into the textile. The invention is also directed to methods of producing the textile, and methods of using the textile to stop bleeding.

The application discloses a medical tissue sealant with biological activity and a preparation method and application thereof, and relates to the field of biomedical technology. The preparation raw material of the medical tissue sealant comprises component A and component B, wherein the component A comprises a polyethylene glycol derivative; and the component B comprises a blood product, and the blood product comprises a blood component and an anticoagulant. The medical tissue sealant can efficiently retain the biological active components inherent in the blood product, such as platelet-derived growth factor and fibrinogen, has the advantages of short gelation time (3-30 seconds), excellent mechanical properties (the compression strength is higher than 800 kPa, the shear strength is higher than 100 kPa, and the anti-burst pressure is higher than 700 mmHg), and moderate degradation time (which can be regulated within 15-30 days), and has a good application prospect in the fields of wound plugging, hemostasis and wound repair.

The invention relates to a method for rapidly preparing exosomes by using human peripheral blood. In one aspect, the method for preparing plasma exosomes from peripheral blood comprises the following steps: (1) rapidly separating plasma components of the peripheral blood obtained from healthy donors or non-specific disease patients by using a differential centrifugation method; (2) performing thermal inactivation to remove a complement system in the plasma; (3) gradually removing impurities (such as substances including protein, polypeptide, fibrinogen and the like) in the plasma by a differential centrifugation method; and (4) precipitating the exosome component in the plasma by a PEG6000 method, and washing the precipitate to obtain the exosome. The invention further relates to the plasma exosome prepared from peripheral blood, the maximum value of particle size distribution of the plasma exosome is within the range of 80-200 nm, the positive rate of CD9-PE is larger than 70%, and the positive rate of CD81-PE is larger than 80%. The method disclosed by the invention can be used for rapidly and efficiently obtaining the exosome from the human peripheral blood.

It is disclosed a method for determining the biological activity of defibrotide, which comprises the steps of: a) bringing into contact defibrotide, mammalian euglobulin and a substrate specific for the plasmin which, by reaction with the plasmin, provides a measurable product; and b) measuring the amount of product formed at successive times, to thereby determine the biological activity of the defibrotide. Liquid defibrotide formulations are also disclosed, preferably water solutions, having a defined biological activity and, in particular, having an activity of 25 to 35 IU / mg of defibrotide, preferably from 27 to 32 IU / mg and, more preferably, from 28 to 32 IU / mg.

A novel targeting process and nanoparticle design is disclosed, improving delivery of drugs and other pay load materials to tumors and other sites of interest. In a preferred embodiment, endothelial cells are damaged at the target site, thereby activating platelets. Nanoparticles bearing fibrinogen or other materials that bind to activated platelets are administered that also contain one or more drugs or other pay load substances thereby improving payload delivery to the targeted site.